Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib for recurrent BRAF V600E-mutant papillary craniopharyngioma
ChiCTR-OPC-17013601Phase 4Not yet recruiting
- Sponsor
- Navy General Hospital
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vemurafenib in Papillary craniopharyngioma (pCP), sponsored by Navy General Hospital. Primary endpoints: Tumor response rate and Progression-free survival. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
vemurafenib
03
Conditions
Papillary craniopharyngioma (pCP)
Beyond the preview
Go deeper on ChiCTR-OPC-17013601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17013601.